Last reviewed · How we verify
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
The primary objectives of this study are (1) to compare the incidence of breast cancer, by insulin use at cohort entry, among females with type 2 diabetes who are new users of dapagliflozin and females who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy and (2) to compare the incidence of bladder cancer, by insulin use at the index date and by pioglitazone use at the index date, among male and female patients with type 2 diabetes who are new users of dapagliflozin and those who are new users of ADs in classes other than SGLT2 inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy. Secondary objectives will compare, by insulin use at cohort entry, frequency of several measures of health care use, baseline characteristics, and incidence of selected other cancers in males and females between the two exposure cohorts.
Details
| Lead sponsor | AstraZeneca |
|---|---|
| Status | COMPLETED |
| Enrolment | 2133575 |
| Start date | Sun Jan 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jan 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Breast Cancer
- Bladder Cancer
Countries
United Kingdom, Netherlands, United States